Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-03

Clinical Trial Update: PRV-3279-2a Trial in Systemic Lupus [Phase 2]

View source ↗

Summary

Provention Bio's PRV-3279-2a Phase 2 trial for systemic lupus erythematosus was terminated, with results posted on 2026-04-03.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PRV-3279-2a

Snippet

Sponsor: Provention Bio, a Sanofi Company | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED | Results posted: 2026-04-03